Pfizer has been struggling for several years. The company's pipeline could help it turn things around. It also has a solid dividend program and is attractively valued. Trading at a bit under $25 ...

It's quite possible for the new year to fulfill this ambitious name. Investing $122,100 in these three high-yield dividend ...

This makes Pfizer a potentially cheap stock to buy while collecting a solid dividend. It's generated about $14 billion in ...

With activist investors gone and revenue stabilizing, the undervalued pharmaceutical giant offers a compelling chance for ...

How $2,670 split across three durable high-yield stocks can generate $300 in annual dividends without risky payouts.

With that, here are two dividend stocks to consider scooping up right now. Image source: Getty Images.

On December 16, Pfizer Inc. (NYSE:PFE) said the next few years are expected to be bumpy, starting in 2026. The company ...

Jim Cramer has built a strong reputation in the industry. He’s the Mad Money host who carefully picks growth stocks that have ...

Dividend stocks have been under pressure in the past few years due to the broader economy’s unpredictable swings. General ...

The New York Times once called John Lamattina, then Pfizer head of R&D, “Dr. Optimistic.” He’s not so optimistic now.

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click for this updated look at PFE stock.

Pfizer now trades well below its pandemic-era multiples, with its valuation anchored to what the business earns today — not what it earned in 2021. The stock yields over 6%, one of the highest payouts ...